Flavoxate Pregnancy and Breastfeeding Warnings

Flavoxate is also known as: Urispas

Flavoxate Pregnancy Warnings

Flavoxate has been assigned to pregnancy category B by the FDA. Animal reproductive studies have failed to reveal evidence of impaired fertility or fetotoxicity. There are no controlled data in human pregnancy. Flavoxate is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.

See references

Flavoxate Breastfeeding Warnings

There are no data on the excretion of flavoxate into human milk.

See references

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.